文献速递炎症性肠病

肌成纤维细胞来源的转谷氨酰胺酶2活性在狭窄型克罗恩病中上调且其抑制具有抗纤维化作用

Myofibroblast-Derived Transglutaminase 2 Activity is Upregulated in Stricturing Crohn's Disease and Its Inhibition Exerts Antifibrotic Properties.
PubMed 文献 · Gastroenterology · 2026-10-13

研究探讨转谷氨酰胺酶2(TG2)在肠纤维化中的作用。在狭窄型克罗恩病患者组织及人肠肌成纤维细胞(HIMF)中测定TG2表达与活性,并在两种实验性纤维化模型中使用诱导性TGM2基因敲除验证。结果显示狭窄型克罗恩病中TG活性增高且高达100%归因于TG2,TG活性与组织纤维化程度相关;HIMF是TG2主要来源(≥95%活性来自TG2);选择性抑制TG2减少纤连蛋白及胶原I、III、VI积累;诱导性TGM2敲除可预防实验性纤维化而不影响肠道炎症程度。结论提示TG2可能参与不依赖炎症的肠纤维化进展。

要点

  • 狭窄型克罗恩病中TG活性增高且高达100%由TG2贡献,并与组织纤维化程度相关。
  • HIMF是TG2主要来源,≥95%的HIMF TG活性来自TG2。
  • 选择性抑制TG2或诱导性TGM2敲除可减少纤维化而不影响肠道炎症。

核心结论

  • TG2可能参与不依赖炎症的肠纤维化进展。

研究设计与样本

  • 比较狭窄型克罗恩病患者与对照的人肠组织及HIMF中TG2表达与活性。
  • 在HIMF中检测TG2抑制剂对ECM积累的影响。
  • 利用bulk RNA测序和单细胞RNA测序发现并功能验证TG2信号通路。
  • 在两种实验性纤维化模型中使用诱导性全局TGM2敲除验证TG2体内作用。

主要发现

  • 狭窄型克罗恩病中TG活性较对照增高,高达100%活性归因于TG2。
  • TG活性与组织病理学纤维化程度相关。
  • HIMF是TG2主要来源,≥95%的HIMF TG活性来自TG2。
  • 单细胞RNA测序证实TG2在肌成纤维细胞中的组织分布。
  • 选择性抑制TG2活性减少HIMF对纤连蛋白及胶原I、III、VI的积累。

临床怎么用

  • TG2活性与纤维化程度相关,或可作为狭窄型克罗恩病纤维化的监测指标。
  • 选择性抑制TG2或可减少ECM积累而不加重炎症,为抗纤维化治疗提供方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Excessive accumulation of extracellular matrix (ECM) derived from human intestinal myofibroblasts (HIMFs) drives the significant clinical problem of intestinal fibrosis. Fibrosis is believed to progress even in the absence of intestinal inflammation. The ECM-bound transglutaminase 2 (TG2) enzyme may exert direct profibrotic effects. We investigated the role of TG2 in intestinal fibrosis. METHODS: TG2 expression and activity in human intestinal tissue and HIMFs from patients with strictured Crohn's disease and control subjects were measured. ECM accumulation by HIMF in the presence or absence of TG2 inhibitors was determined. Putative TG2 signaling pathways discovered in HIMF using bulk RNA sequencing and single-cell RNA sequencing were functionally validated. Role of TG2 in vivo was confirmed using inducible global knockout of TGM2 (encoding TG2) in 2 experimental fibrosis models. RESULTS: Transglutaminase (TG) activity was increased in strictured Crohn's disease compared with controls, with up to 100% activity attributable to TG2. TG activity correlated with the degree of histopathologic tissue fibrosis. HIMFs were the major source of TG2, with ≥95% of HIMF TG activity being derived from TG2. Tissue distribution of TG2 in myofibroblasts was confirmed by single-cell RNA sequencing. Selective inhibition of TG2 activity reduced fibronectin and collagen I, III, and VI accumulation by HIMFs. Novel TG2 signaling pathways revealed by bulk RNA sequencing were functionally validated. Inducible TGM2 knockout prevented experimental fibrosis without affecting the degree of intestinal inflammation. CONCLUSIONS: TG2 may be involved in inflammation-independent progression of intestinal fibrosis.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Chandra J, Czarnecki D, Mukherjee PK, et al. Myofibroblast-Derived Transglutaminase 2 Activity is Upregulated in Stricturing Crohn's Disease and Its Inhibition Exerts Antifibrotic Properties. Gastroenterology. 2026. PMID: 42869257. doi:10.1053/j.gastro.2026.09.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。